Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial☆
Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial☆. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426080762?dgcid=rss_sd_all
Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial☆. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426080762?dgcid=rss_sd_all
“Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial☆.” Annals of Oncology.
@article{article36101,
title = {Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial☆},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426080762?dgcid=rss_sd_all}
}